Lucas Tina, MD, MPH; VIBRI and KEMRI

July 14, 2023
Dr. Lucas Tina is affiliated with the Victoria Biomedical Research Institute (VIBRI) and Kenya Medical Research Institute (KEMRI) in Kisumu, Kenya. Dr. Tina serves as a Scientific Advisory Expert for FHI Clinical, and VIBRI and KEMRI are listed in FHI Clinical’s database of research sites.

This Site and Investigator Spotlight introduces Dr. Lucas Tina, who is affiliated with the Victoria Biomedical Research Institute (VIBRI) and Kenya Medical Research Institute (KEMRI) in Kisumu, Kenya. Dr. Tina serves as a Scientific Advisory Expert for FHI Clinical, and VIBRI and KEMRI are listed in FHI Clinical’s database of research sites, and we are currently working with the sites on vaccine studies for pneumonia, malaria drug trials, tuberculosis surveillance and investigating the outcomes of sepsis.

Dr. Tina and VIBRI were spotlighted in April 2023, and all information on this page is current as of then.

ABOUT DR. TINAABOUT VIBRIABOUT KENYA’S HEALTH PRIORITIES

About Dr. Tina

  • Director and Lead Principal Investigator, VIBRI
  • Deputy Director, Clinical Operations and Physician Investigator, KEMRI/WRP

Dr. Lucas Tina is a physician investigator with 20 years of experience in clinical research for vaccines and therapeutics, public health and epidemiology. He is currently the Director and Lead Principal Investigator (PI) at VIBRI, a non-profit organization based in Kenya. He also works with KEMRI-WRP as a Clinical Research Scientist. He is a Director and Scientific Advisor at ACE Research, a Pan-African clinical research organization (CRO), and serves as a Scientific Advisory Expert for FHI Clinical.
Dr. Tina has been a clinical investigator and leader in several successful drug and vaccine trials including the multi-center, multi-country, Phase 3 RTS, S malaria vaccine trial in Africa. He is currently the Project Lead/Investigator Sponsor for a Coalition for Epidemic Preparedness Innovations (CEPI)-funded, multi-country, Phase 2b COVID-19 vaccine trial currently taking place in Kenya, Rwanda and the Democratic Republic of the Congo. He is also the PI in a Phase 3 COVID-19 vaccine trial in Kenya and the PI in the “Safety and Efficacy Experimental Medicine Trial of the RTS,S/AS01 Malaria Vaccine in Combination with Antimalarials.” He has been an investigator and scientific leader in several highly successful therapeutic and vaccine trials in disease areas including malaria, HIV, tuberculosis, pneumonia, polio, sickle cell disease, diarrhea, Ebola and malnutrition.
Some of the highlights from his career include the clinical trial on the artemether-lumefantrine (COARTEM®) pediatric dispersible tablet, which resulted in regulatory approval by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and regulatory authorities in Africa, and the world’s first malaria vaccine (RTS,S/AS01), which received a positive scientific opinion from the EMA through WHO article 58 and has been recommended for use after undergoing WHO pilot implementation in Africa.
Dr. Tina has been the lead author and co-author of several peer-reviewed publications in prestigious medical journals. Over the years, he has participated in scientific meetings, workshops and conferences including the Pan-African MIM Conference and the American Society of Tropical Medicine and Hygiene (ASTMH) conference. He is a member of ASTMH and a member of the Association of Clinical Research Professionals (ACRP). Dr. Tina has been the recipient of several awards including the Charles C. Shepard Award and the Brian Sharp Award.

He completed his medical training at Moi University School of Medicine and earned an MSc in Public Health in Developing Countries from the London School of Hygiene and Tropical Medicine. He is also an ADVAC (Advanced Course of Vaccinology) Fellow from the Fondation Mérieux and the Université de Genève. He is committed to strengthening community mobilization, education, awareness and involvement in research to improve community health.

Dr. Tina’s publications

Publications over the last ten years include:

About VIBRI

  • Founded in 2020
  • Non-profit African health research institute with a network of clinical trial sites focusing on vaccine, drug, and device research for major global diseases
  • Mission: deliver high-quality health research relevant to Africa and to strengthen health system capacity for undertaking research and providing access to quality health services


VIBRI is located in Kisumu, the third largest city in Kenya and serving a hinterland populated by almost four million people.
Research areas of focus

  • Clinical trials and adaptive trial design for Phase 1-4 trials in both outpatient and inpatient healthcare settings
  • Bioequivalence studies
  • Epidemiology and population health
  • Data science and statistics
  • Implementation science and programs, including monitoring and evaluation, operations research and impact evaluation
  • Training and capacity building to develop African research leadership
Therapeutic areas of focus — communicable diseases

  • Malaria
  • HIV
  • Tuberculosis
  • Pneumonia
  • Diarrheal diseases
  • Emerging infectious diseases such as Ebola, COVID-19, Rift Valley fever
Therapeutic areas of focus — non-communicable diseases

  • Asthma
  • Cardiovascular diseases (e.g., hypertension)
  • Endocrinology, including diabetes mellitus
  • Maternal health
  • Mental health
  • Oncology
  • Sickle cell disease

The disease profile of Kenya


HIV

#1

cause of death

4%

prevalence of HIV among those aged 15-49 years

26%

of new infections affect adolescents and young people (15-24 years)

Malaria

2.7M

cases of malaria in 2020

~75%

of the population at risk of malaria infection

49%

reduction in malaria burden between 2010 and 2020

Diarrheal diseases

#3

cause of death

15%

prevalence in children <5 years old in 2014

Diabetes mellitus

~40%
increase in number of deaths caused from 2009 to 2019
4%

prevalence of diagnosed diabetes mellitus

~44%
proportion of people with undiagnosed diabetes mellitus

Cardiovascular disease

~37%
increase in number of deaths caused by ischemic heart disease from 2009 to 2019
~14%
of all deaths in 2019 caused by cardiovascular disease
Sources:
https://www.usaid.gov/sites/default/files/2022-05/HIV_prevention_fact_sheet_2022.pdf
https://doi.org/10.1016/S0140-6736(20)30925-9
https://www.usaid.gov/sites/default/files/2022-05/Kenya_Malaria_factsheet.pdf
https://www.cdc.gov/globalhivtb/where-we-work/kenya/kenya.html
https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2022/04/Kenya_PMI-Fact-Sheet-InCountry_FY2021_CP-1.pdf
https://www.ijidonline.com/article/S1201-9712(20)30061-8/fulltext
https://diabetesatlas.org/data/en/country/104/ke.html
https://world-heart-federation.org/wp-content/uploads/Kenya-Country-Report.pdf